Imagen de Portada

Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema The Pan-American Collaborative Retina Study Group Results

Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery. Design: Interventional, retrospective, multicenter study.

Detalles Bibliográficos
Autores Principales: Arevalo, J. Fernando, Maia, Mauricio, Garcia-Amaris, Rafael A., Roca, Jose A., Sanchez, Juan G., Berrocal, Maria H., Wu, Lihteh
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Elsevier 2009
Materias:
Aged
80 and over
Angiogenesis Inhibitors
Antibodies
Monoclonal
Humanized
Bevacizumab
Cataract Extraction
Feasibility Studies
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Postoperative Complications
Pseudophakia
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body
Acceso en línea:https://repository.urosario.edu.co/handle/10336/26147
https://doi.org/10.1016/j.ophtha.2009.04.006

Internet

https://repository.urosario.edu.co/handle/10336/26147
https://doi.org/10.1016/j.ophtha.2009.04.006

Ejemplares similares